Jul 25, 2023 8:00am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
Jun 07, 2023 8:05am EDT Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
Jun 06, 2023 8:05am EDT Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
Jun 01, 2023 8:05am EDT Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
May 02, 2023 4:01pm EDT Rigel Reports First Quarter 2023 Financial Results and Provides Business Update
Apr 25, 2023 8:05am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update
Mar 07, 2023 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 28, 2023 8:05am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update
Feb 02, 2023 4:05pm EST Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
